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Background
The aim of this study is to investigate the hematological manifestations of human im-
munodeficiency virus (HIV) infection, the risk factors for cytopenia, and the effect of highly 
active anti-retroviral therapy (HAART) on cytopenia.
Methods
 Medical records of patients treated for HIV at the Seoul National University Hospital from 
January 2005 to March 2010 were retrospectively reviewed. To determine the impact of 
HIV itself, we excluded HIV patients who had other conditions that could have resulted 
in hematological manifestations. Multiple logistic regression analyses were performed 
to identify risk factors for cytopenia.
Results
A total of 621 cases were investigated, and after exclusion, data of 472 patients were 
analyzed. The frequency of cytopenia was anemia, 3.0% (14/472); neutropenia, 10.0% 
(47/472); thrombocytopenia, 2.4% (12/472); lymphopenia, 25.7% (121/470); isolated 
cytopenia, 11.2% (53/472); and bicytopenia, 2.1% (10/472). The leading risk factor for 
cytopenia identified by multivariate logistic regression methods was AIDS status at initial 
presentation. After HAART, cytopenia was reversed in the majority of patients 
(thrombocytopenia, 100%; neutropenia, 91.1%; and anemia, 84.6%).
Conclusion
This study isolated the impact of HIV infection alone on hematologic manifestations and 
confirmed that these changes were reversible by HAART. Control of the HIV infection will 
have the main role in the management of hematological manifestations of the virus.
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INTRODUCTION
Hematologic abnormalities are common in patients with 
advanced human immunodeficiency virus (HIV) infection 
[1] and can affect the outcomes of highly active anti-retro-
viral therapy (HAART), resulting in higher mortality [2-4]. 
Recently, it has been reported that CD4 lymphocyte counts, 
World Health Organization clinical stage, body weight, ane-
mia status, total lymphocyte count, advanced age, and male 
sex are closely related to mortality in sub-Saharan Africa 
[5]. It is well known that CD4 lymphocyte counts are de-
creased during disease progression. However, other hemato-
logic manifestations are not well known. Furthermore, coun-
try and ethnicity may also affect hematological manifes-
tations [6].Korean J Hematol 2011;46:253-7.
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HIV itself can cause hematological manifestations. It has 
been shown that the viral gene products of HIV can indirectly 
influence survival and growth of hematopoietic progenitors 
[1]. Secondary factors such as the effects of medications, 
opportunistic infections, hepatitis B virus (HBV) and hep-
atitis C virus (HCV) co-infection, and liver cirrhosis also 
contribute to hematologic manifestations [2]. Previous stud-
ies have focused on hematologic manifestations without con-
sidering the etiology [7, 8]. In this study, we excluded these 
secondary factors, which may suppress bone marrow and 
focused only on the primary HIV-associated hematologic 
manifestations. The aim of this study was to investigate the 
hematological manifestations of HIV infection, to evaluate 
the risk factors for cytopenia, and to record the effect of 
HAART on cytopenia.
MATERIALS AND METHODS
1. Study population
We collected patient data retrospectively at the Seoul 
National University Hospital in South Korea. The enrollment 
period was from January 2005 to March 2010. Medical record 
of each patient was reviewed to identify eligible patients 
who were diagnosed as having HIV infection and had been 
followed for at least 1 month. Further analysis was done 
for those patients who met eligibility criteria after exclusion. 
The anti-retroviral therapy regimen, HAART, was managed 
by a board-certified infectious disease specialist.
2. Data collection and definition
Medical records were reviewed for demographic data, 
medication history, dates of anti-retroviral therapy, and past 
medical history. All available hematologic values determined 
from peripheral blood analysis were obtained for each patient 
at the beginning of enrollment. Total WBC count, absolute 
neutrophil count (ANC), lymphocyte count, Hb level, and 
platelet count were retrieved from the medical records. 
Plasma HIV RNA titers and CD4- and CD8-T-lymphocyte 
counts were also obtained. Laboratory data were obtained 
at 3 consecutive occasions, i.e., at baseline and then at 6 
months and 3 years after initiation of HAART.
The definitions of cytopenia were as follows: thrombocyto-
penia was defined as platelet count below 100×10
9/L. 
Neutropenia was defined as ANC below 1.5×10
9/L. Anemia 
was defined as a Hb level below 10.0 g/L. Any patient with 
anemia, thrombocytopenia, or neutropenia was defined as 
a patient who had isolated cytopenia. Bicytopenia was de-
fined as the state of a patient in whom any 2 of the 3 
lineage cell counts (ANC, Hb, or platelets) were below the 
levels designated above. Hematological recovery after 
HAART was defined as status at which the cell counts would 
be higher than the cytopenia criteria.
Baseline prothrombin time (PT) with international nor-
malized ratio, activated partial thromboplastin time (aPTT), 
fibrinogen level, and Venereal Disease Research Laboratory 
(VDRL) titers were also retrieved from the medical records. 
The VDRL results were categorized into 3 groups: negative; 
titer ≤1:32; and titer ＞1:32. AIDS was defined in this report 
when CD4 lymphocyte counts were lower than 200/μL. Viral 
load, log10 copies/mL, was categorized as ＜3.5, ＜4.5, ＜5, 
and ≥5, since each group can have each 100 number for 
even distribution.
3. Exclusion
Patients with any conditions other than HIV or AIDS 
that may cause bone marrow suppression or cytopenia were 
excluded. Patients who had received HAART previously 
were also excluded, because the reversal of cytopenia by 
HAART could mask the effects of HIV on the hematological 
status. Exclusion criteria can be summarized as follows: (I) 
patients with opportunistic infection or other signs of in-
fectious illness such as diarrhea, fever, or rash; (II) patients 
with any malignancy such as lymphoma or patients who 
had received chemotherapeutic agents within 6 months prior 
to enrollment; (III) patients with medication history (e.g., 
antibiotics, ganciclovir, trimethoprim-sulfamethoxazole, an-
ti-tuberculosis medications) known to induce cytopenia 
within 2 weeks prior to enrollment; (IV) patients with HBV 
or HCV co-infection or liver cirrhosis; and (V) patients with 
a history of previous HAART.
4. Statistical analysis
Continuous variables were expressed as median and inter-
quartile range (IQR) values. Multiple logistic regression 
methods were used to identify risk factors for cytopenia. 
Univariate analysis was performed for sex, age, progression 
to AIDS at the end of the study, AIDS at the initial stage, 
HIV viral load, log10 copies/mL grade, and VDRL titer with 
the occurrence of cytopenia. The results were reported as 
hazard ratio (HR) and 95% CI (confidence interval). 
Multivariate analysis was performed for variables that had 
P-values lower than 0.1. Hematologic reconstitution after 
HAART was evaluated after treatment. Statistical analyses 
were conducted using SPSS software (version 17.0; SPSS 
Inc., Chicago, IL). A value of P＜0.05 was considered statisti-
cally significant.
5. Ethics statement
The study protocol was approved by the SNUH institu-
tional review board (IRB; No. H-1008-045-326). Informed 
consent was waived by the IRB.
RESULTS
1. Patient characteristics
A total of 621 patients were initially registered from 
January 2005 to March 2010. Median follow-up duration 
was 39.99 months (IQR, 20.24-58.75). In this study, patients 
with any condition other than H I V  o r  A I D S  t h a t  c o u l d  
cause bone marrow suppression or cytopenia were excluded. 
The conditions of patients excluded on the basis of these 
criteria were described in the “Material and Methods” Korean J Hematol 2011;46:253-7.
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Table 1. Baseline characteristics and values.
Characteristics  Study participants after exclusion (N=472) Reference range (SI units)
Age, median years (IQR)      35 (27-44)
Number of female patients (%)      41 (8.7%)
CD4 cell count, median cells/μL (IQR)     300 (175-420) 
Number of immunologic AIDS (%)     134 (28.4%) 
Number of received HAART (%)     389 (82.4%) 
Viral load, log10 copies/mL (IQR)    4.43 (3.60-5.00) 
Absolute neutrophil count, median ×10
9/L (IQR)  2.721 (1.992-3.609) 1.8-7.8×10
9/L
Hb, median g/L (IQR)     147 (134-157)  138-175 g/L
Platelets count, median ×10
9/L (IQR)     209 (177-248)  150-450×10
9/L
Prothrombin time, median INR (IQR)    1.03 (0.97-1.09)  0.8-1.3 INR
Activated PT sec (IQR)  37.00 (33.53-41.70)  22-37 sec
Fibrinogen g/L (IQR)    3.95 (2.96-5.77)  2-4 g/L
Abbreviations: SI units, international system of units; IQR, interquartile range; HAART, highly active anti-retroviral therapy; INR, international 
normalized ratio; PT, prothrombin time.
Table 2. Risk factors for cytopenia (anemia, thrombocytopenia, or neutropenia) by multiple logistic regression methods.
Variable
Patients 
(N)
Univariate analysis by 
logistic regression model
Multivariate analysis by 
logistic regression model
HR 95% CI P HR 95% CI P
Sex Male 431 1.0 - -
Female   41 0.757 0.388-1.476 0.414
Route of transmission Homosexual 208 1.0 - 0.791
Heterosexual 166 1.090 0.705-1.686 0.698
Blood transfusion     2 ＜0.0001 ＜0.0001 0.999
Unknown   96 0.478-1.398 0.461
Age  ＜30 147 1.0 - 0.185
30-39 158 1.601 0.972-2.638 0.065
40-49   88 1.365 0.758-2.459 0.301
≥50   79 1.788 0.989-3.233 0.054
AIDS status at the 
presentation 
CD4 cell count, ＜200
≥200
134
334
8.894
1.0
  5.642-14.020 ＜0.0001 8.520
1.0
5.166-14.052 ＜0.0001
Viral load, log10 copies/mL ＜3.5 103 1.0 - ＜0.0001 1.0 - 0.157
＜4.5 138 0.776 0.430-1.400 0.400 0.659 0.338-1.284 0.220
＜5.0   91 0.906 0.477-1.721 0.763 0.680 0.327-1.416 0.303
≥5.0 116 2.588 1.469-4.560 0.001 1.226 0.621-2.421 0.556
VDRL titer 0 300 1.0 - 0.326
1 (＜1:32)   93 0.742 0.445-1.238 0.254
2 (≥1:32)   43 0.657 0.318-1.358 0.257
Abbreviations: HR, hazard ratio; CI, confidence interval; VDRL, Venereal Disease Research Laboratory test.
section. After exclusion, the total number of enrolled patients 
was 472 and data analysis was performed for these patients.
Baseline characteristics of the patients are listed in Table 
1. The median age was 35 years (IQR, 27-44). The median 
CD4 lymphocyte count was 300/μL (IQR, 175-420), and the 
median log10 HIV RNA virus titer level/mL was 4.43 (IQR, 
3.60-5.00) before initiation of anti-retroviral therapy. In 
28.4% of patients, the CD4 lymphocyte count was below 
200/μL, and this status was defined as immunologic AIDS. 
The percentage of patients who received HAART was 82.4%. 
Median baseline laboratory values are also shown in Table 
1. Values for median WBC count, lymphocyte count, ANC, 
and Hb level were decreased compared to the reference range.
2. Coagulation abnormality
The median value of aPTT and fibrinogen was higher 
than the reference range. Only 2 patients in our cohort 
experienced venous thromboembolic events, and they both 
advanced to the AIDS stage. In addition, 2 patients had 
gastrointestinal bleeding, and 1 patient had intracranial 
hemorrhage. These events of thromboembolism and hemor-
rhage were not related to thrombocytopenia or coagulopathy.Korean J Hematol 2011;46:253-7.
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Table 3. Rates of recovery after HAART.
Type of cytopenia 
Recovery after 
HAART 6 months 
later (recovery/
total number [%])
Recovery after 
HAART 3 years 
later (recovery/
total number [%])
Neutropenia 41/45  (91.1%)  34/37  (91.9%)
Lymphopenia 88/105  (83.8%) 71/76  (93.4%)
Thrombocytopenia 9/9  (100%) 8/8  (100%)
Anemia  10/12 (83.3%)  9/9 (100%)
Isolated cytopenia  44/52 (84.6%)  42/46 (91.3%)
Bicytopenia 9/9  (100%)   8/8  (100%)
Abbreviation: HAART, highly active anti-retroviral therapy.
3. Frequency of cytopenia
The patients were divided according to the subtype and 
frequency of cytopenia. The frequency of cytopenia was 
anemia, 3.0% (14/472); neutropenia, 10.0% (47/472); throm-
bocytopenia, 2.4% (12/472); lymphopenia, 25.7% (121/470); 
isolated cytopenia, 11.2% (53/472); and bicytopenia, 2.1% 
(10/472).
4. Risk factors for cytopenia
We investigated the risk factors for cytopenia. Multiple 
logistic regression methods were used in both multivariate 
and univariate analyses. In univariate analysis, sex, age, route 
of transmission, AIDS status at baseline, HIV viral load (log10 
copies/mL), and VDRL titer were included. AIDS status at 
baseline and HIV viral load (log10 copies/mL) were closely 
associated with cytopenia in the univariate analysis (P＜ 
0.0001). Significant variables (AIDS at the initial stage and 
HIV viral load grades [log10 copies/mL]) that had P-values 
lower than 0.1 were included in the multivariate analysis. 
In the multivariate analysis, only the initial AIDS status 
was significantly correlated with cytopenia (P＜0.0001, 
HR=8.520, 95% CI=5.166-14.052). These results are described 
in detail in Table 2.
5. Effect of HAART
Remarkable hematologic recovery was observed after 
HAART in patients with cytopenia. Among 9 thrombocyto-
penia patients, 8 patients received HAART. Furthermore, 
HAART was given to 13 of 14 patients with anemia, 41 
of 46 patients with neutropenia, and 105 of 121 patients 
with lymphopenia. The percentage of recovery of each cell 
lineage (thrombocytopenia, 100%; neutropenia, 91.1%; ane-
mia, 84.6%; lymphopenia, 83.8%; isolated cytopenia, 84.6%; 
and bicytopenia, 100%) is shown in Table 3. Overall changes 
after 6 months and 3 years were established for each patient. 
After 6 months, 23 patients were lost during follow-up 
(anemia, 2; neutropenia, 1; thrombocytopenia, 2; lymphope-
nia, 16; isolated cytopenia, 1; bicytopenia, 1). Three years 
later, many patients were lost during follow-up. In Table 
3, a denominator was used to describe the total number 
of patients after loss to follow-up.
DISCUSSION
In this study, the types and frequencies of cytopenia were 
examined. In the multivariate analysis, only AIDS status 
at baseline was significantly correlated with cytopenia. As 
in other studies, significant hematologic recovery occurred 
after HAART. Thromboembolic and hemorrhagic events oc-
curred in 2 patients each in whom the infection had advanced 
to the AIDS stage. It has been reported that thromboembo-
lism and hemorrhage are very rare and usually develop in 
the late stage of the disease [9, 10]. The incidence of hemor-
rhage in HIV patients is very low (8%), and intracranial 
hemorrhage has been reported only once in the literature 
[9]. Thus, our result is consistent with that of previous reports.
A low prevalence of cytopenia was reported in South 
Korea. A recent study reported that the prevalence of cytope-
nia in HIV patients receiving HAART in other countries 
was as follows: anemia, 12%; neutropenia, 14%; and throm-
bocytopenia, 7% [6]. This can be partially explained by the 
following reasons. First, the defining values for cytopenia 
in our study are lower than those in previous studies. 
Furthermore, the exclusion of patients with secondary causes 
of cytopenia from our cohort is likely to have reduced the 
prevalence of cytopenia significantly. The frequency of cyto-
penia was higher in the excluded patients than in the included 
patients (anemia, 8.1% [12/149]; neutropenia, 10.7% [16/ 
149]; and thrombocytopenia, 4.7% [7/149]).
In our study, AIDS status at baseline was identified as 
the sole risk factor for cytopenia in the multivariate analysis. 
This finding supports the fact that bone marrow suppression 
and production defects are caused by HIV [1]. It is well 
known that the incidence and severity of cytopenia are gen-
erally correlated with the stage of HIV infection [7]. 
Therefore, this result is consistent with previous studies.
Our study also confirmed the reversal effect of HAART 
on thrombocytopenia, neutropenia, anemia, and lymphocy-
topenia, which again supports the fact that HIV infection 
causes bone marrow suppression and production defects [1]. 
Previous data by Sloand [11] suggests that HIV protease 
inhibitors may have direct effects on hematopoietic stem 
cells. Furthermore, it has been proven that HAART reduces 
HIV viral load and thereby the activity of immune effectors; 
e.g., the anti-proliferative activity by cytokines, and the con-
centration of transferrin receptor of neopterin are decreased. 
It has been demonstrated that the main mechanism of recov-
ery from anemia by anti-retroviral therapy is the decline 
in the activity of immune effectors [12]. HAART decreases 
viral load, which may result in decreased activity of immune 
effectors, thus ameliorating anemia by reversing the anti-pro-
liferative effects of cytokines. This suggests that immune 
reconstruction by control of the HIV viral load is the most 
important step in the management of HIV-related hemato-
logic manifestations. Findings from previous studies have 
also demonstrated that HAART is the most effective means 
for recovery from thrombocytopenia [13]. Furthermore, the 
rate of reversal after HAART in our study was much higher Korean J Hematol 2011;46:253-7.
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than that in previous studies [14]. In patients with HIV 
infection, hematological manifestations may be controlled 
primarily by HIV infection treatments such as HAART.
Compared with previous studies, patients in our study 
had certain unique characteristics. The median age was 35 
years (IQR, 27-44), which was lower than the median age 
reported in studies from other countries (median age=38 
years: IQR, 32-45) [4]. The median CD4 lymphocyte count 
was 295/μL (IQR, 178-410), which is higher than that re-
ported in other countries. In addition, in 28.4% of patients, 
the infection had progressed to the AIDS status. This value 
was lower than that of studies from other countries (47.6%) 
and other Korean studies (37%) [15]. The higher CD4 count 
and lower percentage of AIDS patients was thought to be 
the result of the exclusion of patients with late-stage disease 
who had another infection and/or malignancy. South Korean 
HIV patients have specific characteristics. For instance, in 
HIV-infected Koreans, the primary route of reported HIV 
transmission is through sexual contact (99%), and the pro-
portion of men is 91% [16]. Furthermore, until now, trans-
mission through intravenous drug use has not been reported 
in South Korea. As a result, there were no patients in our 
study who had acquired HIV by intravenous drug use.
The strong points of this study are the lack of intravenous 
drug users and exclusion of patients with secondary causes 
of hematological impairments in HIV infection. Many pre-
ceding studies were conducted in heterogeneous groups that 
consisted of patients reporting various transmission routes, 
including intravenous drug use. Illicit use of intravenous 
drugs is associated with a reduction in the number and func-
tion of platelets even in non-HIV-infected individuals [17]. 
Other factors that may have influenced the hematological 
manifestations of HIV infection were also excluded from 
our study as much as possible. Therefore, our study is the 
first to investigate the impact of HIV infection itself on 
hematological manifestations in clinical situations.
Even though we reviewed all medical records in detail 
to exclude all other potential causes, it is possible that there 
were missed cases or incomplete medical records. Therefore, 
one of the limitations of our study could be the likelihood 
of incomplete exclusion. Another limitation is the tendency 
of retrospective data collection and small study populations 
to restrict statistical significances. Further randomized 
large-scale cohort studies are required in the near future.
In conclusion, on the basis of our study, the frequency 
of HIV-related cytopenia was very low in Korea. All types 
of HIV-related cytopenia were effectively reversed by 
HAART. Furthermore, the risk of cytopenia was related sole-
ly to the stage of HIV infection. Therefore, we propose that 
control of the HIV infection will be the core of the manage-
ment of hematological manifestations of the virus.
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